The Lack of a Relationship Between Physician Payments From Drug Manufacturers and Medicare Claims for Abiraterone and Enzalutamide

Cancer - United States
doi 10.1002/cncr.30914
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Mortality Differences Between Traditional Medicare and Medicare Advantage: A Risk-Adjusted Assessment Using Claims Data

Inquiry
Health Policy
2017English

Axes of Relationship Value Between Manufacturers and Retailers

Management Decision
AccountingManagementOperations ResearchBusinessManagement Science
2018English

Drug Interactions and Enzalutamide

Journal of Pharmacy Practice and Research
PharmacologyPharmacy
2019English

Association Between Physician Characteristics and Payments From Industry in 2015–2017: Observational Study

BMJ Open
Medicine
2019English

Simultaneous Quantitation of Abiraterone, Enzalutamide, N -Desmethyl Enzalutamide, and Bicalutamide in Human Plasma by LC–MS/MS

Journal of Pharmaceutical and Biomedical Analysis
Clinical BiochemistryDrug DiscoveryAnalytical ChemistrySpectroscopyPharmaceutical Science
2017English

Comparison of Medicare Claims Versus Physician Adjudication for Identifying Stroke Outcomes in the Women's Health Initiative

Stroke
CardiologyNeurologyCardiovascular MedicineAdvancedMedicineNeuroscienceSpecialized Nursing
2014English

Medicare Payment for Physician Services

Annals of Internal Medicine
Internal MedicineMedicine
1987English

The Relationship Between Electronic Health Records and Malpractice Claims

Archives of Internal Medicine
2012English

Pd71-06 CTC-Based Gene Expression for Predicting Resistance to Abiraterone and Enzalutamide in McRPC

Journal of Urology
Urology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy